Epizyme Inc (NASDAQ:EPZM) rose 2.4% during mid-day trading on Wednesday . The stock traded as high as $12.60 and last traded at $12.88. Approximately 383,820 shares traded hands during trading, a decline of 55% from the average daily volume of 857,015 shares. The stock had previously closed at $12.58.

EPZM has been the subject of several research reports. BidaskClub raised shares of Epizyme from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. Roth Capital reissued a “buy” rating on shares of Epizyme in a research report on Wednesday, February 27th. Oppenheimer reduced their target price on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, February 27th. Finally, Cowen restated a “buy” rating and set a $18.00 target price on shares of Epizyme in a report on Tuesday, February 26th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $18.90.

The firm has a market capitalization of $1.17 billion, a P/E ratio of -7.52 and a beta of 3.08. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.55 and a current ratio of 12.55.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. The business had revenue of $7.89 million for the quarter, compared to analyst estimates of $1.13 million. Equities research analysts forecast that Epizyme Inc will post -1.96 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Exane Derivatives acquired a new position in Epizyme during the first quarter worth $84,000. Quantamental Technologies LLC acquired a new stake in Epizyme in the fourth quarter valued at $43,000. Legal & General Group Plc lifted its stake in Epizyme by 16.9% in the fourth quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 1,455 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in Epizyme in the first quarter valued at $135,000. Finally, Two Sigma Advisers LP acquired a new stake in Epizyme in the fourth quarter valued at $76,000. Institutional investors and hedge funds own 76.97% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Epizyme (EPZM) Stock Price Up 2.4%” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2019/05/24/epizyme-epzm-stock-price-up-2-4.html.

Epizyme Company Profile (NASDAQ:EPZM)

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

See Also: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.